TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03131037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAN-2409 + valacyclovir
Description: CAN-2409 will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each injection.
Study: NCT01987271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation
Description: A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
Study: NCT03201302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School physical education class
Description: Children participated only in school physical education classes only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taekwondo
Description: Children participated only in taekwondo training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Martial arts
Description: Children participated only in martial arts training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climbing
Description: Children participated only in climbing training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volleyball
Description: Children participated only in volleyball training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artistic gymnastics
Description: Children participated only in artistic gymnastics training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming
Description: Children participated only in swimming training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Children participated only in dance training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basketball
Description: Children participated only in basketball training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrestling
Description: Children participated only in wrestling training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Football (soccer)
Description: Children participated only in football (soccer) training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic gymnastics
Description: Children participated only in rhythmic gymnastics training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Track and field
Description: Children participated only in track and field training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tennis
Description: Children participated only in tennis training only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of activities 1
Description: Children participated in two weight-bearing activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of activities 2
Description: Children participated in one weight-bearing activity and in one non weight-bearing activity.
Study: NCT03400930

Intervention type: OTHER
Intervention: Severe Acute Malnutrition

Intervention type: OTHER
Intervention: Severe Acute Malnutrition

Intervention type: OTHER
Intervention: Severe Acute Malnutrition
Study: NCT01014728

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 100-200mcg/kg/min by infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: 1-3% of sevoflurane (expired)
Study: NCT01490944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron, Folic acid and Cyanocobalamin
Description: Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron and Folic Acid
Description: Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
Study: NCT01460797

Intervention type: OTHER
Group type: OTHER
Intervention: Glycemic Index Diets and Metformin hydrochloride
Description: 1g of Metformin hydrochloride a day in High Glycemic Index Diet

Intervention type: OTHER
Group type: OTHER
Intervention: Glycemic Index Diets and Metformin hydrochloride
Description: 1g of Metformin hydrochloride a day in High Glycemic Index Diet

Intervention type: OTHER
Group type: OTHER
Intervention: Glycemic Index Diets and Metformin hydrochloride
Description: 1g of Metformin hydrochloride a day in High Glycemic Index Diet
Study: NCT02019940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study: NCT02581345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: M923
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Humira
Description: Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
Study: NCT03338972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study: NCT01367340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loaded sit-to-stand resistance exercise
Description: Loaded STS exercise at home, 3 times a week for 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Loaded sit-to-stand resistance exercise
Description: Loaded STS exercise at home, 3 times a week for 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
Study: NCT02515422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Subcutaneous infiltration of ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Subcutaneous infiltration of ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Subcutaneous infiltration of bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Subcutaneous infiltration of bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline solution)
Study: NCT03916094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
Study: NCT00862550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
Study: NCT01132963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outdoor Shoes
Description: Patient will be wearing sturdy outdoor shoes to complete balance tests

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pillow Paw Slippers
Description: Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
Study: NCT02116712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
Study: NCT03490721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clustering care
Description: During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
Study: NCT00148681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Intravenously every week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Intravenously every week for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Every 3 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Every 3 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously every 3 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenously every 3 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly for 12 weeks (or a similar schedule)
Study: NCT00193609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
Study: NCT00411866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB773812
Description: SB-773812 20 mg will be available as white round film coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB773812
Description: SB-773812 20 mg will be available as white round film coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole will be available as 200mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole will be available as 200mg tablets.
Study: NCT01164813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relafen
Description: Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
Study: NCT01075711

Intervention type: DRUG
Intervention: Prednisone
Description: According to SPC

Intervention type: DRUG
Intervention: Prednisone
Description: According to SPC
Study: NCT05039502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protaper Universal Retreatment
Description: D1-D2-D3 Retreatment files were used in 500 rpm and 3 Ncm with X-Smart endomotor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reciproc
Description: R25 retratment files were used with X-Smart endomotor in reciprocal motion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XP-Endo finisher R
Description: XP-Endo finisher r file were used in 1000 rpm 1 Ncm with X-Smart endomotor
Study: NCT00805558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: 400 mg moxifloxacin once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin plus metronidazole
Description: Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
Study: NCT00921336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2450
Description: Dose escalation may proceed once \>= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
Study: NCT03249064

Intervention type: DIAGNOSTIC_TEST
Intervention: CD 91 levels

Intervention type: DIAGNOSTIC_TEST
Intervention: CD 91 levels

Intervention type: DIAGNOSTIC_TEST
Intervention: Tregs

Intervention type: DIAGNOSTIC_TEST
Intervention: Tregs
Study: NCT04031300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Investigational Medical Device collecting spectral Raman data non-invasively from tissue
Study: NCT03080090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
Study: NCT02603783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: capsaicin 1,5 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9% saline 75 ml
Study: NCT03553160

Intervention type: OTHER
Group type: OTHER
Intervention: Frequent Self-Weighing
Description: Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
Study: NCT01214226

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Description: 400 mg prolonged-released tablets 3 time per day for 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: prolonged-release tablets 3 time per day for 1 month
Study: NCT02513797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT + PVI
Description: Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Vein Isolation
Description: Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation
Description: Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
Study: NCT01907009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenograstim
Description: Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days.
Study: NCT03652077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
Study: NCT03354026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-PXZY
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-PXZY
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AICH-PXZY
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-without PXZY
Description: AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-without PXZY
Description: AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AICH-without PXZY
Description: AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-placebo
Description: The placebo is made up of Starch, bitter taste and cyclodextrin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AICH-placebo
Description: The placebo is made up of Starch, bitter taste and cyclodextrin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AICH-placebo
Description: The placebo is made up of Starch, bitter taste and cyclodextrin
Study: NCT01309607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin/lapatinib
Description: Drug doses for the neoadjuvant regimen:~* Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~* Lapatinib 750mg daily continuously
Study: NCT01464866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital food
Description: Typical hospital food given daily at meals
Study: NCT03560544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breaking up sitting
Description: A three-part behaviour change intervention, including:~1. Supportive organisational culture and knowledge of consequence of prolonged sitting~2. Environmental Modification~3. Behavioural Changes
Study: NCT04091971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Subjects will undergo 4 sequential intravenous infusions of ketamine administered over a two week period.~Ketamine is administered at a dose of 0.5mg/kg intravenously as a slow continuous infusion over approximately 40 minutes, with 4 sequential infusions over an approximately two week period (two infusions per week for two weeks).
Study: NCT02303678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2C7-IT
Description: D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
Study: NCT00878397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: School-based delivery of long lasting insecticide nets
Description: Free distribution of long lasting insecticide nets to school children and their younger siblings

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: School-based delivery of long lasting insecticide nets
Description: Free distribution of long lasting insecticide nets to school children and their younger siblings
Study: NCT03567642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100mg/m2 or Etoposide 80mg/m2
Study: NCT03657979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: TAP-block Ropivacaine 0.2% during 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAP-block with placebo